Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

$36.42
-0.85 (-2.28 %)
(As of 01/24/2020 05:15 AM ET)
Today's Range
$35.96
Now: $36.42
$37.28
50-Day Range
$35.03
MA: $42.05
$49.28
52-Week Range
$6.01
Now: $36.42
$59.49
Volume258,400 shs
Average Volume470,845 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta6.79
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.04 per share

Profitability

Net Income$-59,920,000.00

Miscellaneous

Employees82
Market Cap$1.49 billion
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

What price target have analysts set for CNST?

6 brokerages have issued 1 year price targets for Constellation Pharmaceuticals' shares. Their forecasts range from $40.00 to $65.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $49.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

What is the consensus analysts' recommendation for Constellation Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Has Constellation Pharmaceuticals been receiving favorable news coverage?

Media stories about CNST stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Constellation Pharmaceuticals earned a news sentiment score of 3.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Constellation Pharmaceuticals.

Are investors shorting Constellation Pharmaceuticals?

Constellation Pharmaceuticals saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 1,810,000 shares, a decline of 5.7% from the November 28th total of 1,920,000 shares. Based on an average daily volume of 648,100 shares, the days-to-cover ratio is presently 2.8 days. Currently, 15.8% of the company's stock are sold short. View Constellation Pharmaceuticals' Current Options Chain.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Canopy Growth (CGC), AT&T (T), Arrowhead Pharmaceuticals (ARWR), Xilinx (XLNX), Keysight Technologies (KEYS), Kodiak Sciences (KOD), NIO (NIO), Snap (SNAP) and Advanced Micro Devices (AMD).

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the folowing people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
  • Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
  • Dr. Danny Reinberg Ph.D., Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Selz Capital LLC (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

Which institutional investors are buying Constellation Pharmaceuticals stock?

CNST stock was acquired by a variety of institutional investors in the last quarter, including Selz Capital LLC and Nisa Investment Advisors LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $36.42.

How big of a company is Constellation Pharmaceuticals?

Constellation Pharmaceuticals has a market capitalization of $1.49 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]


MarketBeat Community Rating for Constellation Pharmaceuticals (NASDAQ CNST)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel